Working in partnership with the AAC and NICE

There are a range of medicines that people with elevated blood cholesterol can take to help reduce the risk of cardiovascular disease (CVD). We are working in partnership with the Accelerated Access Collaborative (AAC) and the National Institute for Health and Care Excellence (NICE) to ensure appropriate prescribing of all medicines on the lipids management pathway, alongside other factors such as lifestyle changes. The medicines that form the NICE and AAC recommended prescribing pathway for people with high cholesterol levels include bempedoic acid, ezetimibe, high intensity statins, inclisiran, PCSK9i, and statins.

A key ambition for the AHSN Network’s lipids programme is to ensure patients are prescribed the most appropriate medicine in a shared decision with their clinician.

You can see a summary of national guidance for lipid management on the AAC website.

Novel therapies 

During 2021, NICE recommended two novel therapies for patients with elevated cholesterol as part of the lipids management pathway: bempedoic acid and inclisiran. An overview of the collaboration between NHS England and Novartis Pharmaceuticals for the addition of inclisiran to the lipids management pathway is available on the AAC’s webpage.

Dr Phil Jennings, Chief Officer of the Innovation Agency and AHSN Network Lead for the Rapid Uptake Products, explains the new treatment inclisiran in this video for GPs and healthcare professionals*:

*Created to inform healthcare professionals only, to support them to roll-out the treatment.

Contact us

The AHSN Network has a suite of implementation resources available to support the introduction of novel therapies into the lipids pathway. For further information and to get involved in our lipids national programme, please contact us using the contact form for the programme.

Back to national programmes and priorities